Research Highlights:
- A study of three pills that combined two types of blood-pressure-lowering medications into one pill found that all combinations worked equally well among adults in India.
- Results from the TOPSPIN trial found that any two-medication combination lowered most study participants’ blood pressure to 140/90 mm Hg or less.
- Participants were randomly assigned to take a single pill that included either amlodipine and perindopril; perindopril and indapamide; or amlodipine and indapamide. All three treatments proved to be equally effective.
- Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
CHICAGO, Nov. 17, 2024 — Medication variations that combined two of three different blood pressure-lowering medications into a single pill worked equally well in reducing blood pressure and were safe among adults in India, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024. The meeting, Nov. 16-18, 2024, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
High blood pressure is a significant global health burden, affecting 300 million people in India and nearly half of all U.S. adults. Current international hypertension guidelines suggest combining various blood pressure-lowering medications; however, existing research has not determined which combinations offer the best outcomes in South Asian people.
“South Asians account for one-fourth of the world’s population, and India, in particular, has an enormous burden of hypertension, leading to high stroke and cardiovascular disease risk,” said lead TOPSPIN study author Dorairaj Prabhakaran, M.D., D.M., M.Sc., a cardiologist and executive director of the Centre for Chronic Disease Control in New Delhi, India. “Optimal blood pressure management is essential to lower the cardiovascular complications of high blood pressure.”
This clinical trial, called TOPSPIN, was initiated to specifically address high blood pressure among people of South Asian descent. In the multicenter trial in India, almost 2,000 adults were randomly assigned to one of three treatment groups — to receive a single pill, often called a polypill, that included a combination of two commonly recommended medications to lower blood pressure.
Each of the three participant groups was prescribed a pill combining two of these medications: a renin-angiotensin enzyme inhibitor (perindopril), which prevent the arteries from narrowing; calcium channel blockers (amlodipine), which prevent calcium from entering the heart muscle and arteries; and/or diuretics (indapamide), which help the body excrete excess salt and water. The primary outcome measured 24-hour ambulatory systolic blood pressure after taking the combo pill daily for six months.
After six months, the analysis found:
- All three combinations of the medications lowered blood pressure equally, with about 70% of the study participants achieving blood pressure below 140/90 mm Hg.
- More than 40% of participants achieved the stricter blood pressure target of less than 130/80 mm Hg.
- The absolute reduction in blood pressure for participants in all groups was approximately 30/14 mm Hg lower when measured in a physician’s office and 14/8 mm Hg lower when measured using 24-hour ambulatory blood pressure monitors.
- Each of the three combination pills had an excellent safety profile: less than 3% of all study participants reported ending treatment due to adverse effects from the medications. This confirms a high level of tolerability for the medications examined in the trial.
- The participants in the amlodipine-perindopril combination group also experienced a decrease in fasting blood sugar levels after six months.
“It was reassuring to find that all three dual combinations of commonly recommended blood pressure medications were equally effective,” Prabhakaran said. “This is contrary to the findings observed in the CREOLE study that examined the impact of a similar group of three high blood pressure combination pills in Black adults with hypertension in Sub-Saharan Africa and found amlodipine-based combinations to be superior.”
He noted that this study’s strength was that it included participants across India, a wide age range (30-79 years), both men and women, people with and without Type 2 diabetes, and those previously diagnosed and newly diagnosed with hypertension.
Among the study’s limitations is that about 17% of participants did not complete the six-month study.
While this study was conducted in India, it has significant meaning for South Asian adults in the U.S. “More than five million South Asian people live in the U.S., so these findings have huge relevance for them,” Prabhakaran said.
The October 2021 American Heart Association scientific statement, Medication Adherence and Blood Pressure Control, urges health care professionals to evaluate ways to simplify the medication regimen for people with hypertension, such as through prescribing a polypill or a fixed-dose combination pill—one tablet that contains multiple medications.
Study background and details:
- Between 2022 and 2024, 1,981 adults with high blood pressure, ages 30 to 79 (median age 52), 42% women, at 35 hospitals across four regions in India were randomly assigned to receive a single combination pill that included either amlodipine and perindopril; perindopril and indapamide; or amlodipine and indapamide.
- At the time of enrollment, 55% of the participants were already taking some kind of blood pressure-lowering medication, 18.6% had Type 2 diabetes and 6.2% were current smokers.
- Ambulatory blood pressure was measured at enrollment and again at two, four and six months for all participants to study the impact of the blood pressure-lowering medications.
- Patients with diagnosed cardiovascular disease, cerebrovascular disease or kidney conditions were excluded from the study.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
Additional Resources:
###
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for a century. During 2024 - our Centennial year - we celebrate our rich 100-year history and accomplishments. As we forge ahead into our second century of bold discovery and impact, our vision is to advance health and hope for everyone, everywhere. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.